Nurix reports Q3 2026 results as bexobrutideg enters Phase 3 and NX-2127 is droppedOct 13Quarterly updatebexobrutidegNurix Therapeutics, Inc.
Nurix strikes $2.3 billion Roche pact for BTK degrader bexobrutidegJul 9Quarterly updatebexobrutidegNurix Therapeutics, Inc.